The original article [1] contained an error whereby Fig. 4 displayed incorrect magnification scales.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853051 | PMC |
| http://dx.doi.org/10.1186/s13045-018-0587-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer's Disease.
J Prev Alzheimers Dis
November 2024
Anthony O. Caggiano, MD, PhD, Cognition Therapeutics, Inc., 2500 Westchester Avenue, Purchase, NY 10577,
Background: CT1812 is a first-in-class, sigma-2 receptor ligand, that prevents and displaces binding of amyloid beta (Aβ) oligomers. Normalization of quantitative electroencephalography (qEEG) markers suggests that CT1812 protects synapses from Aβ oligomer toxicity.
Objectives: Evaluate CT1812 impact on synaptic function using qEEG measurements.
Austrian consensus statement on the diagnosis and management of hypertrophic cardiomyopathy.
Wien Klin Wochenschr
October 2024
Department of Cardiology and Angiology, Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.
Article Synopsis
- Hypertrophic cardiomyopathy (HCM) is a common heart disease that makes the heart muscle thicker, and it can be inherited from family.
- In Austria, about 20,000 to 40,000 people might have this condition, but it's often hard to diagnose because it shows up in many different ways.
- Early diagnosis and genetic testing are important to help patients and their families, and new treatments are available that can help without surgery.
Concentration-QTc analysis of soticlestat in healthy adults: An alternative to a thorough QT study.
Br J Clin Pharmacol
February 2025
Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA.
Aim: This study aimed to examine the cardiac and overall safety and pharmacokinetic (PK) profiles of soticlestat (TAK-935), an oral, first-in-class selective cholesterol 24-hydroxylase inhibitor.
Methods: Data came from a randomised, phase 1 study of soticlestat in 33 healthy Japanese adults (NCT04461483); 24 adults in Part 1 (single-dose soticlestat 200-1200 mg or placebo) and 9 in Part 2 (soticlestat 100-300 mg twice daily or placebo for 21 days). PK sample collection was paired with 12-lead electrocardiogram data from continuous Holter recordings.
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer.
Ann Oncol
January 2025
Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, USA.
Article Synopsis
- BMS-986365 is a novel oral treatment for metastatic castration-resistant prostate cancer (mCRPC), targeting the androgen receptor (AR) through a unique dual mechanism that both degrades and antagonizes it.
- In a Phase 1 clinical trial involving 95 patients, the drug was found to be well tolerated, with common but manageable side effects, and showed signs of effectiveness, particularly in patients who had not previously undergone chemotherapy.
- The primary goals of the study included assessing safety and determining the highest dose that could be tolerated, while key outcomes such as a significant drop in prostate-specific antigen levels and improved progression-free survival were also evaluated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!